2024-01-21 13:00:39
Published on Jan 21, 2024 at 2:00 p.m.
This biotech specializes in a new approach, that of the intestinal microbiota (fecal transplantation). Resulting from a transfer of know-how from INRA, the specificity of the technology (known as pooling) without equivalent from MaaT Pharma, whose factory has been operational since this summer, is to obtain standardized products containing the complete ecosystem (450 bacteria) from several donors.
Biotech has focused on cancer. Its most advanced product, MaaT013 (in phase III), treats a severe complication linked to allogeneic bone marrow transplantation, graft-versus-host disease (GVHD). It is also being tested (in phase II) in immuno-oncology in metastatic melanoma, because it improves the effectiveness of immunotherapy. For its part, MaaT033 (in phase I) is being evaluated to improve survival for patients with acute leukemia following stem cell transplantation. The year 2024 will be decisive. The interim results (on 75 patients) of the European phase III trial of MaaT013 in AGVHD in patients resistant to reference treatments will be revealed mid-year.
1705852157
#microbiota #attacks #cancer
